BIIB 095
Alternative Names: BIIB-095Latest Information Update: 28 May 2023
At a glance
- Originator Biogen
- Class Analgesics; Small molecules
- Mechanism of Action Nav1.7 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neuropathic pain
Most Recent Events
- 28 May 2023 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in United Kingdom (PO)
- 07 May 2021 BIIB 095 is still in phase I trials for Neuropathic-pain (In volunteers) in United Kingdom (PO) (Biogen Idec pipeline, May 2021)
- 28 Apr 2021 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in United Kingdom (PO)